Outcomes in obesity Among GLP-1RAs, liraglutide, semaglutide, and tirzepatide are licensed for the treatment of obesity
It's designed for people in Stockbridge, Georgia, and beyond who seek a tirzepatide-like effect in pill form, though it utilizes semaglutide instead of tirzepatide
Originally intended for the treatment of type 2 diabetes, clinical trials found that they are also able to treat obesity by significantly decreasing a patients appetite
Gently tap into the skin to absorb
This is why the US medicines regulator, the FDA, lists hair loss explicitly in Section 6.1 of the Wegovy prescribing information as a side effect
4.4 Weight Loss Results / Efficacy Average weight loss of 7.6% with Orlistat 8 versus ~2.0% with placebo at 24 months Over 2 years, 57% of Orlistat users maintained 5% weight loss , versus 9 37.4% in placebo recipients 4.5 Post-GLP1 Use Case 4.5 Post-GLP1 Use Case Direct studies pairing Orlistat with GLP1 tapering are limited, but emerging real-world evidence and pharmacology suggest it can help maintain weight loss: In many patients who transitioned off GLP1 therapy, Orlistat aided in preventing weight regain by continuing fat-blocking effects despite reduced appetite suppression